Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 528

2.

The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.

Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, Manolis AS, Karamitsos DT, Ganotakis ES, Hatseras D; OLYMPIC Study Group.

Angiology. 2005 Nov-Dec;56(6):731-41.

PMID:
16327950
3.

The undertreatment of LDL-cholesterol: addressing the challenge.

Pearson TA.

Int J Cardiol. 2000 Jun 30;74 Suppl 1:S23-8.

PMID:
10856770
5.

Cholesterol: precursor to many lipid disorders.

Jones PH.

Am J Manag Care. 2001 Aug;7(9 Suppl):S289-98. Review.

6.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
7.
8.

Management of dyslipidemia in the high-risk patient.

Stein EA.

Am Heart J. 2002 Dec;144(6 Suppl):S43-50. Review.

PMID:
12486415
9.

Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, Seung KB, Tarasenko L; Lipid Treatment Assessment Project 2 Investigators.

Circulation. 2009 Jul 7;120(1):28-34. doi: 10.1161/CIRCULATIONAHA.108.838466. Epub 2009 Jun 22.

10.
11.

Perspectives on low-density lipoprotein cholesterol goal achievement.

Catapano AL.

Curr Med Res Opin. 2009 Feb;25(2):431-47. doi: 10.1185/03007990802631438 . Review.

PMID:
19192988
12.
13.

Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.

Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Ferrières J, Verdejo J, Chiang CW; L-TAP 2 Investigators.

Am Heart J. 2009 Nov;158(5):860-6. doi: 10.1016/j.ahj.2009.08.009.

PMID:
19853709
14.

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM.

Am J Cardiol. 2005 Aug 15;96(4):556-63.

PMID:
16098311
15.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
17.

[A survey on the status of lipid-lowering therapy in 180 hypercholesterolemic patients].

Cai S, Xia S, Xie H, Yao X, Wang L.

Zhonghua Liu Xing Bing Xue Za Zhi. 2002 Oct;23(5):378-81; discussion 381-2. Chinese.

PMID:
12482372
18.

Cholesterol and atherosclerosis: a contemporary perspective.

Kashyap ML.

Ann Acad Med Singapore. 1997 Jul;26(4):517-23. Review.

PMID:
9395824
19.

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

Am Heart J. 2004 Sep;148(3):447-55.

PMID:
15389231
20.
Items per page

Supplemental Content

Write to the Help Desk